Century Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Century Therapeutics, Inc. (IPSC) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 77.24 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-12
- Century Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 77.50M shares, a 587.45% increase year-over-year.
- Century Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 11.27M shares, a 27.78% increase year-over-year.
- Century Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 8.82M shares, a 22.49% decline year-over-year.
- Century Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 11.38M shares, a 30.07% increase year-over-year.
- Century Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 14.78M shares, a 79.61% increase from fiscal 2024.
- Century Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 8.23M shares, a 34.86% decline from fiscal 2023.
- Century Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 12.64M shares, a 54.38% increase from fiscal 2022.
- Century Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 8.19M shares, a 11.53% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 77.24M shares 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | 77.50M shares 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | 14.78M shares 10-K · filed 2026-03-12 | |||
| 2025-09-30 | 16.06M shares 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | 10.82M shares 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | 11.27M shares 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | 8.23M shares 10-K · filed 2026-03-12 | |||
| 2024-09-30 | 9.56M shares 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | 9.34M shares 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | 8.82M shares 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | 12.64M shares 10-K · filed 2025-03-19 | |||
| 2023-09-30 | 10.86M shares 10-Q · filed 2024-11-05 | |||
| 2023-06-30 | 11.58M shares 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | 11.38M shares 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 8.19M shares 10-K · filed 2024-03-14 | |||
| 2022-09-30 | 8.57M shares 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 8.91M shares 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | 8.75M shares 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | 7.34M shares 10-K · filed 2023-03-16 | |||
| 2021-09-30 | 7.64M shares 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | 7.57M shares 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | 91.16M shares 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | 66.43M shares 10-K · filed 2022-03-17 | |||
| 2020-09-30 | 65.18M shares 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | 65.44M shares 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |